Nancy Lee Bartlett, MD
Current Position
Professor, Medicine
Division of Oncology
Section, Medical Oncology
Specialty Areas
Hematologic Malignancies
Oncology
Lymphoma
Medical Oncology
Mailing Address
|
Washington University School of Medicine
Department of Internal Medicine
660 S. Euclid Avenue, Campus Box 8056
St. Louis,
MO
63110
|
Academic Office
|
NW Tower
Children's Place,
14F
St. Louis,
MO
63110
(314) 362-5654
Fax:
(314) 747-5123
|
Areas of Clinical Interest
Non-Hodgkin's and Hodgkin's lymphoma, chronic lymphocytic leukemia, hematologic malignancies
Board Certification
Internal Medicine
--
Certified
Oncology
--
Certified
Medical Education
B.A.: Chemical Engineering, Stanford University, California, 1978
M.S.: Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, 1979
Medical Degree: Washington University School of Medicine, St. Louis, Missouri, 1986
Residency: Medicine, University of California, San Francisco, California, 1989
Chief Residency: Medicine, University of California, San Francisco, California, 1990
Fellowship: Medical Oncology, Stanford University, California, 1993
Hospital Affiliations
Barnes-Jewish Hospital
Major or Recent Publications/Awards
Honors and Awards
Listed in Best Doctors in America, 2003, 2005 - 2010 (Best Doctors, Inc)
American Cancer Society Career Development Award, 1996-1999
Peer Reviewed Manuscripts
Kahl BS, Bartlett NL, Leonard JP, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD: Bendamustine is effective therapy in patients with rituximab-refractory indolent B-cell non-Hodgkin’s lymphoma: results from a large multicenter study. Blood (submitted)
Halldórsdóttir AM, Spence J, Bartlett NL, Burack WR: High resolution genomic analysis of follicular lymphoma. Genes, Chromosomes, and Cancer (submitted)
Cashen AF, Rubin D, Bartlett NL: Protein losing enteropathy associated with follicular lymphoma of the small bowel. Am J Clin Oncol (in press)
Bartlett NL, Johnson JL, Wagner-Johnston N, Ratain MJ, Peterson BA: Phase II Study of 9-aminocamptothecin in previosuly treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer Chemotherapy and Pharmacology (in press)
Lai R, Bartlett NL, Mackey JR, Jung SH, Johnson JL, Cook JR, Jones D, Cass CE, Young JD, Said J, Cheson B, His ED: High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated in treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine, and liposomal doxorubicin – A CALGB 59804 correlative study. Leuk Lymphoma 2008 Jun: 49(6): 1202-1205
Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, Cheson BD: Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin’s lymphomas: A phase II trial of the CALGB. Br J Haematol 2008: 140: 313-319
Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard J, Bernstein S, Bociek RG, Lorenz JM, Hart BW, Barton J: A phase I multi-dose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008: 111: 1848-1854
Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL: Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and Leukemia Group B Protocol 50206. Leuk Lymphoma 2007: 48: 1313-1319
Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP: Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin (GVD), a salvage regimen in relapsed Hodgkin lymphoma: results of CALGB 59804. Ann Oncol 2007: 8: 1071-1079
Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos G, Cheson BD, Bartlett NL: Sequential Doxorubicin and Topotecan in relapsed/refractory aggressive NHL: Results of CALGB 59906. Leuk Lymphoma 2006: 47: 1511-1517
Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos G, Cheson BD, Bartlett NL: Sequential Doxorubicin and Topotecan in relapsed/refractory aggressive NHL: Results of CALGB 59906. Leuk Lymphoma 2006: 47: 1511-1517
Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA: Rituximab therapy is effective for post-transplant lymphoproliferative disorders after solid organ transplant. Cancer 2005: 104: 1661-1667
Bartlett NL: Therapies for relapsed disease: Transplant and non-transplant approaches including immunotherapy. Hematology 2005: 245-251
Schilder RJ, Molina A, Bartlett NL, Witzig TE, Gordon L, Murray J, Spies S, Wang H, Wiseman G, White CA: Follow-up results of a phase II study of Ibritumomab Tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade follicular, or transformed B-cell non-Hodgkin’s lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 2004: 19: 478-81
Ekstrand BC, Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT, Natkunam Y, Bartlett NL, Horning SJ: Rituximab in lymphocyte predominant Hodgkin’s disease results of a phase II trail. Blood 2003: 101: 4285-4289
Wiseman GA, Leigh BR, Erwin WD, Sparks RB, Podoloff DA, Schilder RJ, Bartlett NL, Spies SM, Grillo-Lopez AJ, Witzig TE, White CA: Radiation dosimetry results from a phase II trial of Ibritumomab Tiuxetan (ZevalinTM) radioimmunotherapy for patients with non-Hodgkin’s lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 2003: 18: 165-178
Ylagan LR, Bartlett NL, Kraus M: Interdigitating dendritic reticulum cell tumor of lymph nodes: Case report with differential diagnostic considerations. Diag Cytopathol 2003: 28: 278-81
Fracasso PM, Blum KA, Tan BR, Fears CL, Bartlett NL, Arquette MA, Clark RS: Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies. Cancer 2002: 95: 2223-2229
Kornblith AB, Kemeny M, Peterson BL, Wheeler J, Crawford J, Bartlett NL, Fleming G, Graziano S, Muss H, Cohen HJ: Survey of oncologists’ perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 2002: 95: 990-996
Wiseman GA, Gordon L, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-Lopez AJ, White CA: Ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma patients with mild thrombocytopenia: a phase II multicenter trial. Blood 2002: 12: 4336-4342
Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA: Randomized controlled trial of Yttrium-90 – labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002: 20: 2453-2463
Selected Invited Publications
Cashen, AF, Bartlett NL: Salvage Regimens for Hodgkin Lymphoma. Clin Advances in Hematology & Oncology 2008 (in press)
Bartlett NL, Fenske, T: " Tumors and Masses: Lymphoma". In: Pearson et al, (eds.). Thoracic Surgery, 3rd ed., W.B. Saunders Company 2007: 1622-1633
Bartlett NL, Wagner-Johnston, N: “Lymphoma”. In: Govindan R, (eds.). The Washington Manual of Oncology, 2nd ed., Lippincott Williams & Wilkins, 2007: 286-303
Cashen AF, Bartlett NL: Therapy of Relapsed Hodgkin Lymphoma. Blood Reviews 2007: 21: 233-243
Bartlett NL: Management of Advanced Hodgkin’s Lymphoma: “Not One Size Fits All”. In: Perry MC, Govindan R (eds.) American Society Clinical Oncology Educational Book 2006
Smukler AJ, Bartlett NL: “Management of advanced stage Hodgkin’s lymphoma”. In: Cancer Treatment and Research 2006: 131: 333-352
Blum KA, Bartlett NL: 90 Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodkin’s lymphoma. Expert Opinion on Biological Therapy 2004: 4(8): 1323-1331
Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, Vo K, Theuer C, Pohlman B, Bartlett NL, Wiseman G, Mohamed D, White C: Yttrium 90-labeled Ibritumomab Tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clinical Lymphoma 2004: 5: 98-101
Bartlett NL: New therapies in Hodgkin’s lymphoma. Clinical Advances in Hematology & Oncology 2004: 2: 80-83
Bartlett NL: Escalated BEACOPP: Two Steps Forward, One Step Back. American Journal of Oncology Review 2004: 2: 119-123
Blum KA, Bartlett NL: Hodgkin’s Disease: Chemotherapy. In: Rakel R, Bope E, (eds.) Conn’s Current Therapy, W.B. Saunders Company, 2004
Blum KA, Bartlett NL: Targeting CD30 in Patients With Hodgkin’s Lymphoma. Biological Therapy of Lymphoma 2003: 6: 11-14
Blum KA, Bartlett NL: Antibodies for the Treatment of Diffuse Large Cell Lymphoma. Seminars in Oncology 2003: 30: 445-456
Bartlett NL: Hodgkin’s disease module. PIER-ACP, 2003
Blum KA, Bartlett NL: Extranodal marginal zone (MALT) lymphoma. Contemporary Oncology 2002: 1: 1-8
Wagner ND, Bartlett NL: “Lymphoma”. In: Govindan R, Arquette M, (eds.). The Washington Manual of Oncology, Lippincott Williams & Wilkins, 2002
Bartlett NL, Wagner ND: "Tumors and Masses: Lymphoma". In: Pearson et al, (eds.). Thoracic Surgery, 2nd ed., W.B. Saunders Company, 2002
Bartlett NL, Arackal SM: “Macroglobulinemia”. In: Austen FK, Frank MM, Atkinson JP, Cantor H, (eds.). Samter’s Immunologic Diseases, 6th ed., Lippincott Williams & Wilkins, 2001
For more articles and abstracts, take this off-site link to the National Library of Medicine Pub Med page for Dr. Bartlett